16:34 EDT Bicara Therapeutics (BCAX) files $400M mixed securities shelf
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
- Bicara Therapeutics initiated with a Buy at JonesResearch
- Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
- Bicara Therapeutics initiated with an Overweight at Piper Sandler